CME Group
CME
$277.24
-1.18%
CME Group Inc. operates the world's largest derivatives marketplace, providing investors, businesses, and institutions with the ability to trade futures and options across interest rates, equity indexes, foreign currencies, energy, metals, and agricultural commodities. As the dominant exchange operator in global derivatives, CME holds a structural moat anchored by its clearinghouse, deep liquidity pools, and exclusive rights to trade S&P futures contracts through its 27% stake in S&P Dow Jones Indexes. The current investor narrative is heavily shaped by the Federal Reserve's hawkish pivot under Chair Kevin Warsh, where rising rate-hike expectations simultaneously boost hedging and trading volumes on CME's platforms while also pressuring valuation multiples across financial equities. Recent headlines emphasize the tug-of-war between elevated inflation forecasts, tariff-driven cost pressures, and a cooling labor market, all of which drive volatility and, by extension, transaction volumes through CME's clearing and transaction fee engine.…
CME
CME Group
$277.24
Related headlines
Investment Opinion: Should I buy CME Today?
The synthesized recommendation for CME is a Hold, reflecting a balanced risk-reward profile. The analyst consensus rating of 'buy' with a mean of 2.47 and an average target price of $289.06 implies only 3.0% upside from the current price of $280.56, suggesting limited near-term appreciation potential. While the company's dominant market position and exceptional profitability are undeniable, the modest growth trajectory and premium valuation warrant a cautious stance.
The supporting evidence for a Hold is compelling: CME trades at a trailing PE of 24.43x and forward PE of 21.60x, at a premium to the broader financial sector. Revenue growth is anemic at 0.84% year-over-year, and gross margin has compressed from 88.14% to 69.25% sequentially. However, the company generates massive free cash flow ($4.21 billion TTM) and maintains a fortress balance sheet with a debt-to-equity of 0.13. The dividend yield of 4.0% and consistent buybacks provide shareholder returns, but the payout ratio of 97.25% limits future increases. The low beta of 0.27 offers downside protection, but the stock's 1-year relative strength versus SPY is -11.64%, indicating underperformance.
The biggest risks that could invalidate the Hold rating include a sustained decline in trading volumes due to Fed rate hikes, further margin compression, and multiple contraction if growth disappoints. The rating would upgrade to Buy if the forward PE compresses below 20x or if revenue growth accelerates above 5% year-over-year. Conversely, a downgrade to Sell would occur if revenue growth turns negative or if the payout ratio exceeds 100%, signaling financial stress. Relative to its own history, the current PE of 24.43x is near the middle of its historical range (18.7x-32.8x), suggesting the stock is fairly valued, but the premium to peers and the low growth rate leave little margin for error.
Sign up to view all
CME 12-Month Price Forecast
CME presents a balanced risk-reward profile with a neutral stance. The company's dominant market position and exceptional profitability are offset by sluggish revenue growth and a premium valuation. The analyst consensus target of $289.06 implies only 3% upside, and the wide target range ($217-$337) reflects uncertainty. The low beta and strong cash flows make it a defensive holding, but the lack of a clear growth catalyst limits near-term appreciation. I would upgrade to bullish if revenue growth accelerates above 5% or if the forward PE compresses below 20x, and downgrade to bearish if trading volumes decline significantly or if margins compress further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $289.06 and implied upside of +4.3% versus the current price.
Average Target
$289.06
0 analysts
Implied Upside
+4.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$217 - $337
Analyst target range
CME is covered by 16 analysts, with a consensus recommendation of "buy" and a recommendation mean of 2.47 on a scale where 1 is a strong buy and 5 is a strong sell. The average target price is $289.06, which implies approximately 3.0% upside from the current price of $280.56. This modest upside suggests that the consensus view is cautiously optimistic but not overwhelmingly bullish, reflecting the balanced risk-reward profile of a low-beta, mature exchange operator. The Buy/Hold/Sell distribution is not explicitly provided, but the recommendation mean of 2.47 indicates a lean toward the buy side, though it is not a strong conviction call. The target price range spans from a low of $217.00 to a high of $337.00, representing a wide spread of approximately 55% between the bear and bull cases. The high target of $337.00 assumes multiple expansion and accelerating trading volumes, potentially driven by sustained market volatility and increased hedging activity amid Fed rate hikes. The low target of $217.00 prices in margin compression, competitive pressures, and a potential decline in trading volumes if market volatility subsides. Recent institutional ratings show a mix of actions, with TD Cowen reiterating Buy ratings in September 2026, while Deutsche Bank downgraded from Buy to Hold in August 2026, and both JP Morgan and B of A Securities maintained Underweight and Underperform ratings, respectively. This divergence in analyst opinions, combined with the wide target range, signals elevated uncertainty about CME's near-term trajectory, though the low beta and strong fundamentals provide a degree of downside protection.
Bulls vs Bears: CME Investment Factors
The bull case for CME rests on its unassailable market position, exceptional profitability, and defensive characteristics, while the bear case centers on sluggish growth, premium valuation, and interest rate risks. Currently, the bear evidence appears slightly stronger due to the modest 0.84% revenue growth, margin compression, and the high payout ratio that limits financial flexibility. The most critical tension is the trajectory of trading volumes amid Fed policy: if rate hikes stimulate hedging activity and volatility, CME could see revenue acceleration and multiple expansion; however, if rate hikes suppress market activity and compress valuations, the stock could struggle to justify its premium. The low beta and strong cash flows provide downside protection, but the lack of a clear growth catalyst keeps the risk-reward balanced.
Bullish
- Dominant Moat and Structural Advantage: CME operates the world's largest derivatives marketplace with exclusive rights to trade S&P futures through its 27% stake in S&P Dow Jones Indexes. This creates a near-monopoly in key products, supported by a clearinghouse that ensures deep liquidity and high barriers to entry.
- Exceptional Profitability and Cash Generation: Q2 2026 net income was $1.042 billion with a net margin of 61.06%, and trailing twelve-month free cash flow reached $4.21 billion. Operating margin of 64.89% and gross margin of 86.09% (TTM) highlight the operating leverage inherent in the exchange model.
- Fortress Balance Sheet and Capital Returns: Debt-to-equity is only 0.13 and the current ratio is 92.97, indicating minimal financial risk. In Q2 2026 alone, CME returned $468.1 million in dividends and $698.2 million in buybacks, while maintaining a massive cash position.
- Low Beta Defensive Profile: With a beta of 0.27, CME is approximately 73% less volatile than the broader market, providing downside cushioning during selloffs. This makes it an attractive holding for risk-averse investors seeking stable returns.
Bearish
- Sluggish Revenue Growth: Q2 2026 revenue grew only 0.84% year-over-year to $1.706 billion, reflecting a mature, saturated market. Sequential revenue declined from $1.880 billion in Q1 2026, highlighting seasonal volatility and limited organic growth prospects.
- Premium Valuation with Limited Margin for Error: The trailing PE of 24.43x and forward PE of 21.60x are at a premium to the broader financial services sector. The PEG ratio of 1.59 indicates the stock trades above its growth rate, leaving little room for disappointment.
- Margin Compression and High Payout Ratio: Gross margin fell from 88.14% in Q1 2026 to 69.25% in Q2 2026, and the payout ratio is 97.25%, limiting flexibility for future dividend increases. This suggests earnings growth may be constrained without significant revenue acceleration.
- Interest Rate Sensitivity and Macro Headwinds: The Fed's hawkish pivot under Chair Warsh raises the risk of rate hikes that could dampen trading volumes and compress valuation multiples. Recent news highlights inflation reacceleration and tariff-driven cost pressures, which could reduce market volatility and trading activity.
CME Technical Analysis
CME is in a broad range-bound consolidation with a modest upward bias, having gained 4.36% over the past year while trading at approximately 62.5% of its 52-week range (low of $218.31, high of $329.16). The current price of $280.56 sits well below the 52-week high, suggesting the stock has not fully recovered from its mid-year drawdown of -33.05%, which is a significant peak-to-trough decline for a low-beta name. This positioning implies the stock is neither overextended nor deeply discounted, but rather in a neutral zone where the market is awaiting a clearer directional catalyst. Recent momentum has been constructive, with a 1-month gain of 2.13% and a strong 3-month gain of 16.77%, indicating a sharp recovery from the June-July lows near $218. However, the 6-month change of -4.99% reveals that the intermediate-term trend remains negative, creating a divergence where short-term strength is offset by longer-term weakness. The 1-month relative strength versus SPY is a marginal +0.01%, essentially in line with the market, while the 3-month relative strength of +13.64% highlights meaningful outperformance during the recovery phase. This pattern suggests a potential trend reversal is underway, but it has not yet been confirmed by a break above the 6-month downtrend. Key resistance lies at the 52-week high of $329.16, and a breakout above that level would signal a full trend reversal and likely attract momentum buyers. Support is anchored at the 52-week low of $218.31, and a breakdown below that level would confirm a resumption of the bearish trend and likely trigger further selling. With a beta of just 0.27, CME is approximately 73% less volatile than the broader market, making it a defensive holding that typically underperforms in strong bull markets but provides downside cushioning during selloffs. This low beta, combined with the wide 52-week range, suggests that position sizing can be larger relative to high-beta names, but the stock's sensitivity to interest rate policy remains a key risk factor.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
+2.1%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +1.8% |
| 3m | +13.8% | +3.5% |
| 6m | -6.6% | +11.2% |
| 1y | +2.1% | +19.1% |
| ytd | +2.8% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue trajectory shows modest but positive growth, with Q2 2026 revenue of $1.706 billion representing a 0.84% year-over-year increase from $1.692 billion in Q2 2025. Sequentially, revenue declined from $1.880 billion in Q1 2026, reflecting the seasonal nature of trading volumes, but the multi-quarter trend from Q3 2025 ($1.538 billion) through Q2 2026 shows a general upward drift. The clearing and transaction fees segment dominates the revenue mix at $1.353 billion, followed by market data at $238 million and other revenue at $116 million, underscoring CME's reliance on trading activity as its primary growth engine. The modest 0.84% YoY growth rate suggests the company is in a mature, steady-state phase rather than a high-growth trajectory, which is typical for a dominant exchange operator with limited room for organic market share expansion. Profitability remains exceptional, with Q2 2026 net income of $1.042 billion and a net margin of 61.06%, reflecting the inherent operating leverage of the exchange model. Gross margin stands at 69.25% for the quarter, though this is lower than the 86.09% trailing figure, likely due to quarterly fluctuations in cost of revenue. Operating margin is a robust 64.89%, and the company consistently converts a high proportion of revenue into profit, with net income exceeding $1 billion for the fourth consecutive quarter. The slight compression in gross margin from 88.14% in Q1 2026 to 69.25% in Q2 2026 warrants monitoring, but the overall profitability profile remains among the strongest in the financial services sector. CME's balance sheet is fortress-like, with a debt-to-equity ratio of just 0.13 and a current ratio of 92.97, indicating overwhelming short-term liquidity. Free cash flow for Q2 2026 was $923.5 million, and the trailing twelve-month FCF stands at $4.21 billion, providing ample internal funding for dividends, buybacks, and strategic investments. The company returned capital aggressively in Q2 2026, paying $468.1 million in dividends and repurchasing $698.2 million in stock, while still maintaining a massive cash position of $160.26 billion. ROE of 14.08% is solid for a capital-light exchange, and the low debt burden means financial risk is minimal, though the high payout ratio of 97.25% suggests limited room for significant dividend increases without corresponding earnings growth.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+0.8%
YoY Comparison
Gross Margin
69.3%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Since CME's net income is positive at $1.042 billion, the PE ratio is the primary valuation metric. The trailing PE stands at 24.43x, while the forward PE is 21.60x, implying the market expects earnings growth of approximately 13.1% over the next year. This forward discount to trailing earnings suggests that analysts anticipate EPS expansion, likely driven by continued trading volume growth and operating leverage. The PEG ratio of 1.59 indicates that the stock is trading at a premium to its growth rate, which may be justified by the company's dominant market position and consistent cash generation. Compared to the broader financial services sector, CME's trailing PE of 24.43x is at a premium to the industry average, though precise peer data is not available in the provided dataset. The PS ratio of 15.06x and EV/EBITDA of 16.89x are elevated, reflecting the market's willingness to pay up for CME's stable, recurring revenue streams and wide moat. The price-to-book ratio of 3.42x is moderate for a company with such high margins, but the premium across most multiples suggests that investors are pricing in continued operational excellence and capital returns. Historically, CME's PE ratio has ranged from a low of approximately 18.7x in Q3 2021 to a high of 32.8x in Q4 2021, with the current 24.43x sitting near the middle of that band. The PS ratio has been more volatile, ranging from 45.8x in Q2 2024 to 71.4x in Q4 2021, and the current 15.06x appears to be at the low end of the historical range, though this may be due to changes in revenue recognition or segment reporting. The current valuation does not appear stretched relative to CME's own history, but the premium to the broader market leaves little room for disappointment, especially if interest rate hikes dampen trading volumes or if margin compression continues.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.9x
Enterprise Value Multiple
Investment Risk Disclosure
CME's financial risks are relatively contained but not negligible. The debt-to-equity ratio of 0.13 and current ratio of 92.97 indicate a fortress balance sheet, yet the payout ratio of 97.25% leaves little room for dividend growth without earnings expansion. Revenue growth of just 0.84% year-over-year in Q2 2026, combined with a sequential decline from $1.880 billion to $1.706 billion, highlights the company's dependence on trading volumes, which are inherently cyclical. Additionally, the gross margin compression from 88.14% in Q1 2026 to 69.25% in Q2 2026, if sustained, could pressure profitability, though net margin remains robust at 61.06%.
Market and competitive risks are significant given CME's premium valuation. The trailing PE of 24.43x and forward PE of 21.60x are above the industry average, leaving the stock vulnerable to multiple compression if growth disappoints. The beta of 0.27 suggests low correlation with the broader market, but interest rate hikes under Fed Chair Warsh could reduce trading volumes and volatility, directly impacting CME's transaction fees. Recent news highlights inflation reacceleration and tariff-driven cost pressures, which could lead to a hawkish Fed and lower market activity. Furthermore, competition from other exchanges and alternative trading venues could erode CME's market share over time, though its exclusive S&P futures contract provides a strong moat.
The worst-case scenario for CME involves a combination of declining trading volumes, margin compression, and multiple contraction. If the Fed raises rates aggressively, market volatility could decline as investors reduce hedging activity, leading to lower transaction fees. Simultaneously, if revenue growth turns negative and margins compress further, the stock could re-rate to its historical low PE of 18.7x, implying a price near $217 (the analyst low target). From the current price of $280.56, this represents a downside of approximately 22.6%. A more severe scenario, such as a broad market selloff or a loss of key contracts, could push the stock toward its 52-week low of $218.31, a decline of 22.2%. The maximum drawdown over the past year was -33.05%, indicating that in a severe downturn, losses could exceed 30%.
FAQ
The key risks include: 1) Financial risk from a high payout ratio of 97.25%, which limits dividend growth and financial flexibility; 2) Market risk from premium valuation (forward PE of 21.60x) and potential multiple compression if growth disappoints; 3) Macro risk from Fed rate hikes under Chair Warsh, which could reduce trading volumes and volatility; and 4) Competitive risk from alternative trading venues eroding market share, though the exclusive S&P futures contract provides a strong moat. The most severe risk is a combination of declining volumes and margin compression, which could push the stock down 22% to the 52-week low of $218.31.
The 12-month forecast for CME includes three scenarios: a bull case (25% probability) with a target range of $320-$337, driven by increased volatility and trading volumes; a base case (55% probability) with a target range of $280-$295, assuming steady-state performance and a PE of 24x; and a bear case (20% probability) with a target range of $217-$230, resulting from declining volumes and multiple contraction. The base case is most likely, with the key assumption that the Fed pauses rate hikes and trading volumes grow modestly. The analyst average target of $289.06 aligns with the base case.
CME appears fairly valued relative to its own history but slightly overvalued compared to the broader financial sector. The trailing PE of 24.43x is near the middle of its historical range (18.7x-32.8x), while the forward PE of 21.60x suggests modest earnings growth expectations. The PEG ratio of 1.59 indicates the stock trades at a premium to its growth rate, and the PS ratio of 15.06x is elevated. The market is pricing in continued operational excellence and stable cash flows, but with revenue growth below 1%, the valuation leaves little room for disappointment. A re-rating to the low end of the historical PE range would imply a price near $217.
CME is a good buy for conservative, income-focused investors seeking low volatility and stable dividends, but it may not be ideal for those seeking high growth. The stock offers a 4.0% dividend yield and trades at a forward PE of 21.60x, with a consensus target price of $289.06 implying 3.0% upside. However, revenue growth is only 0.84% year-over-year, and the payout ratio is 97.25%, limiting future dividend increases. The biggest downside risk is a decline in trading volumes due to Fed rate hikes, which could push the stock toward its 52-week low of $218.31, a 22% drop. Overall, it's a solid defensive holding but not a high-growth opportunity.
CME is more suitable for long-term investment due to its low beta (0.27), stable dividend yield (4.0%), and wide moat, which provide steady returns over time. Short-term trading is less attractive given the modest upside to analyst targets and the stock's range-bound technical pattern. The company's earnings visibility is high, but growth is slow, making it a buy-and-hold candidate for income and stability. A minimum holding period of 2-3 years is recommended to ride out cyclical downturns and benefit from consistent capital returns. However, investors should monitor Fed policy and trading volume trends, as these can impact short-term performance.